Clinical Edge Journal Scan

RA raises the risk for end-stage renal disease


 

Key clinical point: Rheumatoid arthritis (RA) is associated with a high risk for end-stage renal disease, with the risk being prominent among relatively young and comorbidity-free individuals and those who consume alcohol.

Major finding: Patients with RA were at a significantly higher risk for end-stage renal disease compared with those without RA (adjusted hazard ratio 2.153; 95% CI 1.948-2.379), particularly among patients who were relatively young (Pinteraction < .001), those without comorbidities (Pinteraction < .001), and those who consumed alcohol (Pinteraction = .021).

Study details: This retrospective population-based study included 154,997 patients with RA and 774,985 age- and sex-matched individuals without RA.

Disclosures: This study was supported by grants from the Chonnam National University Hospital Biomedical Research Institute and National Research Foundation of Korea, funded by the Korea Government. The authors declared no conflicts of interest.

Source: Suh SH et al. Rheumatoid arthritis and the risk of end-stage renal disease: A nationwide, population-based study. Front Med (Lausanne). 2023;10:1116489 (Feb 2). Doi: 10.3389/fmed.2023.1116489

Recommended Reading

Commentary: Glucocorticoid use and progression in RA, February 2023
MDedge Rheumatology
Systemic sclerosis antibodies show link to interstitial lung disease in RA
MDedge Rheumatology
Prehospital COVID therapy effective in rheumatic disease patients
MDedge Rheumatology
UnitedHealthcare tried to deny coverage to a chronically ill patient. He fought back, exposing the insurer’s inner workings.
MDedge Rheumatology
Biosimilars perform identically to originator biologics in natural experiment
MDedge Rheumatology
Health plans get very poor scores for access to autoimmune drugs
MDedge Rheumatology
Sarilumab shows long-term safety and efficacy in RA
MDedge Rheumatology
Concomitant methotrexate-glucocorticoid raises bacterial infection risk in RA patients taking bDMARD
MDedge Rheumatology
Treat-to-target management improves cardiovascular outcomes in early RA
MDedge Rheumatology
Pregnant women with RA and their infants at risk for adverse outcomes and rehospitalization
MDedge Rheumatology